1. Articles from ncbi.nlm.nih.gov

  2. 49-72 of 1715 « 1 2 3 4 5 6 ... 70 71 72 »
    1. Transcription factor activating protein 4 is synthetically lethal and a master regulator of MYCN-amplified neuroblastoma.

      Transcription factor activating protein 4 is synthetically lethal and a master regulator of MYCN-amplified neuroblastoma.

      Oncogene. 2018 Jun 07;:

      Authors: Boboila S, Lopez G, Yu J, Banerjee D, Kadenhe-Chiweshe A, Connolly EP, Kandel JJ, Rajbhandari P, Silva JM, Califano A, Yamashiro DJ

      Read Full Article
      Mentions: MYCN
    2. Predicting clinical outcome of neuroblastoma patients using an integrative network-based approach.

      Predicting clinical outcome of neuroblastoma patients using an integrative network-based approach.

      Biol Direct. 2018 Jun 07;13(1):12

      Authors: Tranchevent LC, Nazarov PV, Kaoma T, Schmartz GP, Muller A, Kim SY, Rajapakse JC, Azuaje F

      Abstract BACKGROUND: One of the main current challenges in computational biology is to make sense of the huge amounts of multidimensional experimental data that are being produced.

      Read Full Article
    3. Neonatal neuroblastoma 4s with diffuse liver metastases (Pepper syndrome) without an adrenal/extraadrenal primary identified on imaging.

      Neonatal neuroblastoma 4s with diffuse liver metastases (Pepper syndrome) without an adrenal/extraadrenal primary identified on imaging.

      J Radiol Case Rep. 2018 Mar;12(3):18-27

      Authors: Chaturvedi A, Katzman PJ, Franco A

      Abstract We report the imaging appearances of a case of pathologically proven, neonatal neuroblastoma 4S with diffuse hepatic metastatic involvement at presentation. Patient had an abnormal appearing liver both by ultrasound and MR.

      Read Full Article
      Mentions: Imaging MIBG
    4. Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma.

      Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma.

      Oncoimmunology. 2018;7(6):e1433518

      Authors: Quintarelli C, Orlando D, Boffa I, Guercio M, Polito VA, Petretto A, Lavarello C, Sinibaldi M, Weber G, Del Bufalo F, Giorda E, Scarsella M, Petrini S, Pagliara D, Locatelli F, De Angelis B, Caruana I

      Read Full Article
    5. miR-129 inhibits tumor growth and potentiates chemosensitivity of neuroblastoma by targeting MYO10.

      miR-129 inhibits tumor growth and potentiates chemosensitivity of neuroblastoma by targeting MYO10.

      Biomed Pharmacother. 2018 Jul;103:1312-1318

      Authors: Wang X, Li J, Xu X, Zheng J, Li Q

      Abstract Although the treatment strategies for neuroblastoma (NB) develop rapidly, a considerable number of patients could not benefit from chemotherapy. Here, we revealed a miR-129-MYO10 axis that regulated neuroblastoma growth and chemosensitivity.

      Read Full Article
    6. Erythropoietin enhances migration of human neuroblastoma cells: in vitro studies and potential therapeutic implications.

      Erythropoietin enhances migration of human neuroblastoma cells: in vitro studies and potential therapeutic implications.

      J Cancer Stem Cell Res. 2017;5:

      Authors: Poniewierska-Baran A, Rajewska-Majchrzak J, Ratajczak MZ

      Abstract The erythropoietin receptor (EpoR) is expressed by cells from the erythroid lineage; however, evidence has accumulated that it is also expressed by some other non-hematopoietic tissues including several solid tumor cells and proposed candidates for cancer stem cells. This is an important concern, because recombinant erythropoietin (EPO) is frequently employed in cancer patients as a drug to ameliorate anemia related to chemo/radiotherapy. In our studies, we employed three human neuroblastoma ...

      Read Full Article
      Mentions: Radiotherapy
    7. Convolutional Deep Belief Network with Feature Encoding for Classification of Neuroblastoma Histological Images.

      Convolutional Deep Belief Network with Feature Encoding for Classification of Neuroblastoma Histological Images.

      J Pathol Inform. 2018;9:17

      Authors: Gheisari S, Catchpoole DR, Charlton A, Kennedy PJ

      Abstract Background: Neuroblastoma is the most common extracranial solid tumor in children younger than 5 years old. Optimal management of neuroblastic tumors depends on many factors including histopathological classification.

      Read Full Article
    8. Tune Up In Situ Autovaccination against Solid Tumors with Oncolytic Viruses.

      Tune Up In Situ Autovaccination against Solid Tumors with Oncolytic Viruses.

      Cancers (Basel). 2018 May 31;10(6):

      Authors: Nguyen T, Avci NG, Shin DH, Martinez-Velez N, Jiang H

      Abstract With the progress of immunotherapy in cancer, oncolytic viruses (OVs) have attracted more and more attention during the past decade.

      Read Full Article
    9. Association of Common Genetic Variants in Pre-microRNAs and Neuroblastoma Susceptibility: A Two-Center Study in Chinese Children.

      Association of Common Genetic Variants in Pre-microRNAs and Neuroblastoma Susceptibility: A Two-Center Study in Chinese Children.

      Mol Ther Nucleic Acids. 2018 Jun 01;11:1-8

      Authors: He J, Zou Y, Liu X, Zhu J, Zhang J, Zhang R, Yang T, Xia H

      Abstract Neuroblastoma is a commonly occurring extracranial pediatric solid tumor without defined etiology. Polymorphisms in pre-miRNAs have been demonstrated to associate with the risk of several cancers.

      Read Full Article
    10. Predicting survival times for neuroblastoma patients using RNA-seq expression profiles.

      Predicting survival times for neuroblastoma patients using RNA-seq expression profiles.

      Biol Direct. 2018 May 30;13(1):11

      Authors: Grimes T, Walker AR, Datta S, Datta S

      Abstract BACKGROUND: Neuroblastoma is the most common tumor of early childhood and is notorious for its high variability in clinical presentation. Accurate prognosis has remained a challenge for many patients. In this study, expression profiles from RNA-sequencing are used to predict survival times directly.

      Read Full Article
    11. Both serum and tissue Galectin-1 levels are associated with adverse clinical features in neuroblastoma.

      Both serum and tissue Galectin-1 levels are associated with adverse clinical features in neuroblastoma.

      Pediatr Blood Cancer. 2018 May 24;:e27229

      Authors: Chen K, Cai Y, Zhang M, Wu Z, Wu Y

      Abstract BACKGROUND: Neuroblastoma is one of the most common pediatric solid tumors. Although the 5-year overall survival rate has increased over the past few decades, high-risk patients still have a poor prognosis due to a lack of biomonitoring therapy.

      Read Full Article
    12. Clinical significance of MYCN amplification in patients with high-risk neuroblastoma.

      Clinical significance of MYCN amplification in patients with high-risk neuroblastoma.

      Pediatr Blood Cancer. 2018 May 24;:e27257

      Authors: Lee JW, Son MH, Cho HW, Ma YE, Yoo KH, Sung KW, Koo HH

      Abstract BACKGROUND: This study investigated the clinical significance of MYCN amplification within high-risk neuroblastoma (NB). METHODS: Medical records of 135 patients who were diagnosed with high-risk NB from 2004 to 2016 were reviewed.

      Read Full Article
      Mentions: MYCN NSE
    13. A 3-Protein Expression Signature of Neuroblastoma for Outcome Prediction.

      A 3-Protein Expression Signature of Neuroblastoma for Outcome Prediction.

      Am J Surg Pathol. 2018 May 22;:

      Authors: Xie Y, Xu H, Fang F, Li Z, Zhou H, Pan J, Guo W, Zhu X, Wang J, Wu Y

      Abstract Neuroblastoma (NB) is the most common extracranial solid tumor in children with contrasting outcomes. Precise risk assessment contributes to prognosis prediction, which is critical for treatment strategy decisions.

      Read Full Article
      Mentions: Treatment
    14. MicroRNA-1247 inhibits cell proliferation by directly targeting ZNF346 in childhood neuroblastoma.

      MicroRNA-1247 inhibits cell proliferation by directly targeting ZNF346 in childhood neuroblastoma.

      Biol Res. 2018 May 24;51(1):13

      Authors: Wu T, Lin Y, Xie Z

      Abstract BACKGROUND: Neuroblastoma (NB) represents the most common extracranial solid tumor in children. Accumulating evidence shows that microRNAs (miRs) play an important role in the carcinogenesis of NB. Here, we investigated the biological function of miR-1247 in NB in vitro.

      Read Full Article
    15. Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T Cell Receptors in High-risk MYCN-not-amplified Human Neuroblastoma.

      Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T Cell Receptors in High-risk MYCN-not-amplified Human Neuroblastoma.

      Clin Cancer Res. 2018 May 21;:

      Authors: Wei JS, Kuznetsov IB, Zhang S, Song YK, Asgharzadeh S, Sindiri S, Wen X, Patidar R, Nagaraj S, Walton A, Guidry Auvil JM, Gerhard DS, Yuksel A, Catchpoole DR, Hewitt SM, Sondel PM, Seeger RC, Maris JM, Khan J

      Read Full Article
      Mentions: MYCN
    16. Methylation of DNA and chromatin as a mechanism of oncogenesis and therapeutic target in neuroblastoma.

      Methylation of DNA and chromatin as a mechanism of oncogenesis and therapeutic target in neuroblastoma.

      Oncotarget. 2018 Apr 24;9(31):22184-22193

      Authors: Ram Kumar RM, Schor NF

      Abstract Neuroblastoma (NB), a developmental cancer, is often fatal, emphasizing the need to understand its pathogenesis and identify new therapeutic targets.

      Read Full Article
    17. Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma.

      Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma.

      Sci Transl Med. 2018 May 16;10(441):

      Authors: Lochmann TL, Powell KM, Ham J, Floros KV, Heisey DAR, Kurupi RIJ, Calbert ML, Ghotra MS, Greninger P, Dozmorov M, Gowda M, Souers AJ, Reynolds CP, Benes CH, Faber AC

      Read Full Article
      Mentions: MYCN
    18. Emerging role of immunotherapy for childhood cancers.

      Emerging role of immunotherapy for childhood cancers.

      Chin Clin Oncol. 2018 Apr;7(2):14

      Authors: Handgretinger R, Schlegel P

      Abstract Recent developments in cell and gene therapy have a great impact on the new therapeutic approaches in pediatric cancers. Monoclonal antibodies for neuroblastoma and bispecific antibodies for leukemia have induced significant clinical responses for otherwise chemorefractory patients.

      Read Full Article
      Mentions: Immunotherapy
    19. Cancer Treatment and End-of-Life Care.

      Cancer Treatment and End-of-Life Care.

      J Palliat Med. 2018 May 16;:

      Authors: Sinha S, Matharu JK, Jacob J, Palat G, Brun E, Wiebe T, Segerlantz M

      Abstract AIM: To study to what extent tumor-specific treatment (chemo- or radiotherapy) was given during the last 30 days in life and to examine how many of the patients were referred to a specialized palliative care unit (PCU), at a low-resource governmental hospital in India.

      Read Full Article
    20. PHOX2B Is A Reliable Immunomarker in Distinguishing Peripheral Neuroblastic Tumors From CNS Embryonal Tumors.

      PHOX2B Is A Reliable Immunomarker in Distinguishing Peripheral Neuroblastic Tumors From CNS Embryonal Tumors.

      Histopathology. 2018 May 14;:

      Authors: Alexandrescu S, Paulson V, Dubuc A, Ligon A, Lidov HG

      Abstract INTRODUCTION: The PHOX2B gene regulates neuronal maturation in the brain stem nuclei associated with cardiorespiratory function, and in the autonomic sympathetic and enteric nervous system.

      Read Full Article
      Mentions: MYCN PHOX2B
    21. MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma.

      MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma.

      Oncotarget. 2018 Apr 17;9(29):20323-20338

      Authors: Agarwal S, Milazzo G, Rajapakshe K, Bernardi R, Chen Z, Barberi E, Koster J, Perini G, Coarfa C, Shohet JM

      Abstract The MYC oncogenes and p53 have opposing yet interrelated roles in normal development and tumorigenesis. How MYCN expression alters the biology and clinical responsiveness of pediatric neuroblastoma remains poorly defined.

      Read Full Article
      Mentions: MYCN Tumorigenesis
    22. Evolving biopsy techniques for the diagnosis of neuroblastoma in children.

      Evolving biopsy techniques for the diagnosis of neuroblastoma in children.

      J Pediatr Surg. 2018 Apr 14;:

      Authors: Campagna G, Rosenfeld E, Foster J, Vasudevan S, Nuchtern J, Kim E, Commander S, Naik-Mathuria B

      Abstract BACKGROUND/PURPOSE: To compare the adequacy and safety of percutaneous core needle biopsy and surgical wedge biopsy of neuroblastoma in children.

      Read Full Article
      Mentions: Treatment Biopsy
    49-72 of 1715 « 1 2 3 4 5 6 ... 70 71 72 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video